2023/07/03 - Financial public releases
Virbac reassesses its 2023 growth and Adjusted EBIT1 forecast
Several elements are currently impacting our business and leading us today to revise our forecasts for the 2023 financial year. As a reminder, at constant rates and scope, our initial forecast for revenue growth was within a range of between 4% and 6% while our initial forecast for ratio of Adjusted EBIT1 was within a range of between 13% and 14%. We now expect revenue growth at constant rates and scope within a range of between 0% and 4%. The ratio of Adjusted EBIT1 should now consolidate within a range of between 12% and 13% at constant exchange rates.
On the one hand, we confirm the overall market growth slowdown observed during the first quarter, with decreasing volumes in many geographies while compared to 2022. On the other hand, we are facing production capacity’s limitations for dog and cat vaccines, temporary however larger than expected throughout this first semester. This situation weighs on our fixed costs’ absorption as well as on our sales, given our low level of vaccine stocks. In addition to that, there is also the impact linked to the cyberattack of which we were victims on June 19, though we are not yet able to precisely measure all its consequences. Our teams remain fully mobilized to ensure business continuity and implement remediation plans with deployments currently executed with efficiency and speed.
All of these elements prevent us from envisaging a catch-up by the end of the year, hence leading us today to adjust our sales forecasts for the year 2023 and subsequently our forecasts of Adjusted EBIT. The momentum of our activity remains positive in many geographies and we also remain confident about the group's 2030 forecasts that remain unchanged.
 “current operating profit before amortization of assets resulting from acquisitions” to “revenue” ratio